据中国日报报道，12月27日，中核集团在苏州举办核技术医学转化与临床应用大会，并与苏州市联合宣 布：我国首个核医疗示范基地——苏州大学附属第二医院（核工业总医院）浒关院区二期项目正式启 用。核工业总医院浒关二期集核技术精准诊疗、临床试验、医学创新、培训交流功能于一体，聚焦核医 疗及肿瘤、慢病防治等重点方向。 公司方面，据中证报表示，景业智能、中广核技等。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 中证报指出，核医疗正迎来政策红利与技术突破的双重催化，随着中国在核素制备、核药研发及核医疗 设备领域的自主化突破，核医疗产业将迎来加速发展。中国核医疗市场预计2025-2030年将保持高速增 长，到"十五五"末，年产值有望达到6000亿元左右。 ...

东诚药业回复：您好，二级市场股价变化受宏观环境、市场情绪、行业变化等多种因素综合影响。公司 将切实履行信息披露义务，加强投资者沟通，积极向市场传递公司声音，始终坚持高质量发展战略，通 过提升经营效率和盈利能力，增强公司核心竞争力，以实现长期价值增长。感谢您的关注与建议！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，东诚药业(002675)12月22日在投资者关系平台上答复投资者关心的问题。 投资者提问：尊敬的董秘：您好！近期东诚药业股价持续走低至新低，广大股民亏损累累，内心焦灼万 分。公司虽有核药研发推进、产品获批及纳入医保等进展，但业绩短期承压仍让市场信心不足。作为长 期信任公司的投资者，恳请您重视股价现状，通过更充分的信息披露传递发展价值，积极采取维稳措 施。盼公司切实兼顾长期发展与股东权益，缓解股民困境。希望公司能真切考虑我们 拿出一些实际行 动 不要只是回答的很官方！ ...

Core Viewpoint - The development of radiopharmaceuticals is revolutionizing cancer treatment, allowing targeted delivery of radiation to tumor cells while minimizing damage to surrounding healthy cells [1][2][3]. Industry Overview - Radiopharmaceuticals, which contain radioactive isotopes, are becoming a strategic focus in the biopharmaceutical industry globally, with major pharmaceutical companies entering the field [3][4]. - The global radiopharmaceutical market is projected to grow from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% from 2024 to 2029 [3]. Clinical Application - The treatment process involves imaging techniques like SPECT or PET to locate tumors and determine the appropriate dosage of radiopharmaceuticals, which are then administered to the patient [5]. - The integration of diagnosis and treatment, referred to as "diagnosis-therapy integration," is a key feature that distinguishes radiopharmaceutical therapy from existing cancer treatment methods [5]. Market Dynamics - The international market has validated the value of radiopharmaceuticals, exemplified by the approval and success of Pluvicto in the U.S. for treating metastatic castration-resistant prostate cancer, generating $271 million in its first year [6]. - In China, as of February 2024, only three innovative radiopharmaceuticals have been approved, highlighting a lag in innovation compared to international counterparts [7][8]. Challenges and Opportunities - The development of innovative radiopharmaceuticals is hindered by the need for collaboration across the supply chain, including the availability of imaging equipment and isotopes [8][9]. - Recent government initiatives aim to enhance the infrastructure for radiopharmaceuticals, including plans for comprehensive coverage of nuclear medicine departments in hospitals by 2025 [10][11]. Innovations and Developments - Companies like Shanghai United Imaging Healthcare have made significant advancements in high-end imaging equipment, contributing to the rapid proliferation of PET technology in China [11]. - Domestic production of isotopes is improving, with companies like China National Nuclear Corporation and Yuan Da Pharmaceutical achieving mass production of various isotopes [12]. Future Outlook - The Chinese radiopharmaceutical industry is expected to enter a phase of accelerated development, with over 205 innovative radiopharmaceuticals currently in clinical stages [12][18]. - Multiple companies, including Fosun Pharma and Baiyang Pharmaceutical Group, are actively expanding their presence in the radiopharmaceutical sector, indicating a robust growth trajectory [14][15][16].

Core Viewpoint - The development of radiopharmaceuticals is revolutionizing cancer treatment, allowing targeted delivery of radiation to tumor cells while minimizing damage to surrounding healthy cells [1][3]. Industry Overview - The global nuclear medicine market is projected to grow from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% from 2024 to 2029 [2]. - Major pharmaceutical companies worldwide, including domestic firms like Fosun Pharma and Yanda Pharmaceutical, are actively entering the nuclear medicine sector [2]. Clinical Application - The clinical application of radiopharmaceuticals involves imaging techniques such as SPECT and PET to locate tumors and determine the appropriate dosage of nuclear medicine [3]. - The integration of diagnosis and treatment, referred to as "diagnosis-therapy integration," is a key feature that distinguishes nuclear medicine from traditional cancer treatments [3]. Innovation and Development - Companies are developing products that utilize different isotopes for both diagnosis and treatment, creating a closed-loop system for cancer precision therapy [4]. - The domestic market has seen a significant increase in the number of innovative radiopharmaceuticals, with 205 pipelines currently in clinical stages as of February 2024 [9][12]. Challenges and Solutions - The lack of domestic production capabilities for medical isotopes and imaging equipment has historically limited the development of innovative radiopharmaceuticals in China [5][6]. - Recent government policies aim to enhance the infrastructure and supply chain for nuclear medicine, including plans for comprehensive coverage of nuclear medicine departments in hospitals by 2025 [7][8]. Market Dynamics - The domestic PET market has seen substantial growth, with a reported 722 PET machines in use as of 2023, an increase of 80.8% since 2019 [8]. - Companies like United Imaging Healthcare have made significant advancements in the development of high-end imaging equipment, contributing to the proliferation of PET technology in medical institutions [8]. Collaborative Efforts - Multiple companies, including Fosun Pharma and Baiyang Pharmaceutical Group, are forming partnerships and investing in the nuclear medicine sector to accelerate innovation and market entry [12]. - The collaboration between pharmaceutical companies and government entities is expected to enhance the development and application of radiopharmaceuticals in China [12].

Core Insights - The development of radiopharmaceuticals is revolutionizing cancer treatment by allowing targeted delivery of radiation to tumor cells while minimizing damage to surrounding healthy cells [1][3] - The global radiopharmaceutical market is projected to grow from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% from 2024 to 2029 [2] - The integration of diagnosis and treatment in nuclear medicine, referred to as "diagnosis-therapy integration," is a key feature that distinguishes it from existing cancer treatment methods [3][4] Industry Landscape - Major global pharmaceutical companies have entered the radiopharmaceutical sector, with domestic companies like Fosun Pharma, Yanda Pharmaceutical, and China Isotope & Radiation Corporation actively positioning themselves [2] - As of February 2024, there are 205 innovative radiopharmaceuticals in clinical development in China, indicating a significant increase in research and development activity [9][10] Challenges and Solutions - The lack of domestic production capabilities for medical isotopes and imaging equipment has hindered the development of innovative radiopharmaceuticals in China [6][8] - Recent government policies aim to enhance the infrastructure for nuclear medicine, including the development of imaging equipment and stable supply of medical isotopes [7][8] Innovations and Collaborations - Companies like Yanda Pharmaceutical and Baiyang Pharmaceutical are making strides in developing innovative radiopharmaceuticals and establishing comprehensive industry chains [10][11] - The establishment of partnerships and platforms, such as Fosun Pharma's nuclear medicine platform, is expected to accelerate the development and commercialization of radiopharmaceuticals [11]

Core Insights - The Sichuan government is prioritizing the development of the nuclear medicine industry, aiming to establish a world-class nuclear medicine industrial hub [3][4] - New policy measures have been introduced to address challenges in the nuclear medicine sector, focusing on regulatory efficiency, innovation, market demand, and a supportive environment [3][5][6] Regulatory Efficiency - Six measures have been proposed to enhance regulatory efficiency, including the establishment of a more scientific and effective regulatory system [3] - The government aims to streamline regulations for new treatment technologies, such as Flash radiation therapy, and support the development of relevant guidelines [3][4] Innovation Empowerment - Four measures are focused on fostering innovation in the nuclear medicine sector, including support for research on new drug targets and the establishment of integrated platforms for industry-academia-research collaboration [4] - The government encourages joint innovation among industry players to enhance the overall development of the nuclear medicine field [4] Expanding Market Demand - Seven measures aim to stimulate end-user demand, which is expected to drive growth across the entire nuclear medicine supply chain [5][6] - Initiatives include promoting the application of domestic nuclear medical equipment in hospitals and encouraging the development of commercial insurance products related to nuclear medicine [6] Supportive Environment - Seven measures are designed to create a favorable environment for the nuclear medicine industry, including the establishment of a consultation mechanism for the industry chain and the promotion of government investment funds [6][7] - The government plans to address financing challenges faced by nuclear medicine enterprises by leveraging policy financial tools and encouraging public-private partnerships [7]

Group 1 - The core focus is on the high-quality development of the private economy, emphasizing the need for precise policies to address the challenges faced by private enterprises [1] - The "Technology Commissioner" initiative in Yantai Huangbohai New Area aims to support high-level talent collaboration and innovation, particularly in the nuclear medicine sector [3][4] - Dongcheng Pharmaceutical has established a collaborative innovation mechanism with Yantai Harbin Engineering University to overcome talent shortages in nuclear medicine [3][4] Group 2 - The partnership has led to the development of over 10 types of medical isotopes and the publication of 4 SCI papers, with two patents currently under application [3] - Dongcheng Pharmaceutical is actively developing over 10 new nuclear drugs, including a key project "177Lu-LNC1004 targeted radioactive innovative drug" that has received clinical approval in multiple countries [3][4] - The collaboration has enhanced the supply of nuclear medicine talent and expanded the talent pool, contributing to the growth of the nuclear medicine industry [5]

Core Viewpoint - China Dongfang (01763.HK) reported a revenue of RMB 2.858 billion for the six months ending June 30, 2025, representing a year-on-year increase of 2% [1] Financial Performance - Gross profit amounted to RMB 1.460 billion, showing a slight decrease of 0.3% year-on-year [1] - Profit attributable to equity shareholders was RMB 172 million, reflecting an increase of 11.3% year-on-year [1] - Basic earnings per share were RMB 0.54 [1] Margin Analysis - The gross margin decreased from 52.1% to 51.1% [1] - The decline in gross profit and gross margin was primarily due to a reduction in revenue from nuclear medicine, while other business segments with higher revenue growth had lower gross margins, which negatively impacted the overall gross margin [1]

Core Viewpoint - China Dongfang (01763) reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The company's profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year, with basic earnings per share of 0.54 RMB [1] - A mid-term dividend of 0.0807 RMB per share is proposed [1] Group Focus - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core businesses: radionuclides, radiopharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] Business Operations - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1] - It provides services such as irradiation sterilization, material modification, and the design, manufacturing, installation engineering, procurement, and construction (EPC) services of irradiation devices [1] - Additionally, the company offers nuclear medical equipment and construction services for nuclear medicine departments to hospitals and other medical institutions [1]

Group 1 - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year [1] - The basic earnings per share were 0.54 RMB, and the company proposed an interim dividend of 0.0807 RMB per share [1] Group 2 - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core business areas: radionuclides, nuclear pharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1]